peptides
KPV 10mg
KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-MSH. Research focuses on NF-κB suppression, mucosal/gut-barrier integrity, and dermal inflammation without melanocortin pigmentation effects.
Research-observed benefits
- ›NF-κB pathway modulation
- ›Gut-barrier research
- ›Dermal inflammation models
- ›No pigmentation activity
Findings reported in in-vitro / preclinical research literature. Not therapeutic claims.
CAS Number
—
Purity
99%+
Molecular Formula
—
Stock
120 units
Order type
Purchase option
Quantity
Total
$35
For in-vitro research only. Not for human consumption, diagnostic, or therapeutic use. Storage at -20°C recommended for lyophilized peptides.
KPV 10mg — Full Research Breakdown
Tailored information for researchers. All content is for in-vitro / preclinical research context only — not medical advice.
Mechanism of Action
Lys-Pro-Val, the C-terminal tripeptide of alpha-MSH. Enters cells via PepT1 transporters and inhibits NF-κB and MAPK inflammatory cascades without activating melanocortin pigmentation receptors.
How It Helps
Delivers alpha-MSH's anti-inflammatory activity while avoiding tanning and cardiovascular melanocortin effects — a clean tool for mucosal and dermal inflammation research.
Half-Life
Short plasma presence; local tissue activity persists notably longer
Onset of Effects
Inflammatory-marker shifts commonly observed within 1–3 weeks.
Storage
Lyophilized: –20°C. Reconstituted: 2–8°C, 30 days.
Stacks Well With
- ›BPC-157 (gut-lining research)
- ›TB-500 (tissue remodeling)
Research-Observed Side Effects
- •Minimal reported; occasional injection-site redness
Translational Cautions
- •Limited human translational data
Research Highlights
- ▸Reduces colonic inflammation in DSS-colitis murine models.
- ▸Demonstrated antimicrobial activity against candida and staph strains in vitro.
- ▸Topical models show reduced dermal cytokine expression.